Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study

What Was Tested

This randomized controlled trial paper looks at Insulin Lispro and Amylin (Islet Amyloid Polypeptide).

Who Took Part

According to the abstract, 19 subjects were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 2 diabetes using insulin lispro underwent five consecutive mixed-meal tests.

In randomized order, subjects received subcutaneous injections of placebo at -15 min or 120-microg pramlintide at -15, 0, +15, or +30 min relative to the standardized breakfast after an overnight fast.

How the Study Was Run

In design terms this was a randomized, single-blind, placebo-controlled and crossover study.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the subjects, was kept unaware of whether Insulin Lispro was given.

The comparison arm used a placebo, so changes seen with Insulin Lispro could be set against what happens without it.

In the crossover set-up each of the subjects took both Insulin Lispro and the comparison in turn, acting as their own control.

Plasma glucose concentrations were measured before and during the 4-h postmeal period.

What Was Measured

The subject headings attached to it are Amyloid, Area Under Curve, Blood Glucose, Body Mass Index, Diabetes Mellitus, Diabetes Mellitus, Type 2 and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Insulin Lispro and Amylin (Islet Amyloid Polypeptide) in 19 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (Diabetes/metabolism research and reviews), a journal based in England.

More context: the Insulin Lispro compound page and the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.